Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
294.8 AUD | +0.36% |
|
+0.65% | +2.87% |
25/06 | Finland to start bird flu vaccinations for humans | RE |
21/06 | Mining, gold stocks lift Australian shares; c.bank's hawkish stance caps gains | RE |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The company is in debt and has limited leeway for investment
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 52 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.87% | 93.98B | A- | ||
-3.42% | 37.69B | A- | ||
-13.75% | 32.99B | B- | ||
+73.19% | 28.27B | A | ||
-11.88% | 16.17B | C | ||
+0.49% | 14.33B | B- | ||
-12.95% | 11.44B | D+ | ||
+190.36% | 10.96B | D | ||
-54.07% | 9.26B | B | ||
+5.17% | 8.96B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CSL Stock
- Ratings CSL Limited